Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

0(0%)

Results Posted

33%(1 trials)

Terminated

1(20%)

Phase Distribution

Ph early_phase_1

20%

Ph phase_2

20%

Ph phase_4

40%

Ph phase_3

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Early Phase 1First-in-human

1(20.0%)

Phase 2Efficacy & side effects

1(20.0%)

Phase 3Large-scale testing

1(20.0%)

Phase 4Post-market surveillance

2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(1)

Other(1)

Detailed Status

Completed3

Terminated1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (20.0%)

Phase 21 (20.0%)

Phase 31 (20.0%)

Phase 42 (40.0%)

Trials by Status

terminated120%

unknown120%

completed360%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_3

Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)

NCT03841357

completedphase_4

Clinical Trials (5)

Showing 5 of 5 trials

NCT03841357Phase 3

Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)

Completed

NCT03669367Phase 4

EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study)

Completed

NCT04255134Phase 4

Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)

Completed

NCT03059888Early Phase 1

Trial of Orencia in Patients With Myasthenia Gravis

Terminated

NCT04120831Phase 2

TOLERA: Tolerance Enhancement in RA

Unknown

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5